GE Healthcare Announces Strategic Partnerships with Process Analysis and Automation and MatriCal
News Jan 17, 2008
These partnerships will enable GE Healthcare to further extend its offering with the most comprehensive range of cellular analysis and automation solutions for the IN Cell Analyzer platform.
As PAA is a specialist in the automation field, this partnership will allow GE Healthcare to provide customers with a range of automation solutions for the company’s IN Cell Analyzer and LEADseeker platforms.
Components are matched, installations are co-ordinated and customers no longer have to work with multiple vendors to build an automation platform for high content analysis (HCA) and high throughput screening (HTS).
With the strategic supplier agreement with MatriCal, GE Healthcare can now offer 96 and 384 well, flat glass bottom microwell plates at a competitive rate. The flat glass bottom MatriPlates™ have the benefit of providing, low auto-fluorescence, evenness of the plate surface, and optimum optical viewing surface for cell based assays. Combined with the advanced highly sensitive IN Cell Analyzer imaging platform, optimal imaging performance can be achieved.
“These partnerships and agreements allow GE Healthcare to deliver complete solutions to our customers that are able to meet their specific requirements, whether they need automated systems or key accessories for their high content analysis workflow. This will enable customers to undertake cellular analysis with the optimum image quality and the highest efficiency,” said Ger Brophy, General Manager of Advanced Systems at GE Healthcare Life Sciences.
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE